| Features: |
| 5-FU is a chemotherapy medication used to treat various types of cancer, including colorectal, breast, stomach, and pancreatic cancer. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and replication of cancer cells. Mechanisms: - irreversibly inhibits Thymidylate Synthase (TS), thereby depleting the deoxythymidine monophosphate (dTMP) pool required for DNA synthesis. The resulting “thymineless death” prevents DNA replication and repair, particularly affecting rapidly proliferating tumor cells. 5-FU is a cornerstone in chemotherapy with a dual mechanism of action—primarily inhibiting thymidylate synthase (leading to disruption of DNA synthesis) and interfering with RNA processing by misincorporation. Its metabolism via activation (OPRT) and degradation (DPD) plays a crucial role in both its effectiveness and toxicity. Clinically, 5-FU is extensively used in treating a variety of cancers, most notably colorectal cancer, and remains a mainstay in multi-agent chemotherapeutic regimens due to its proven efficacy across diverse cancer types. 5-FU is one of the most common chemotherapeutic agents worldwide, particularly noted in gastrointestinal (GI) cancers. |
| - | in-vitro, | CRC, | NA |
| 233- | AL, | 5-FU, | Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway |
| - | in-vivo, | Liver, | NA |
| 1009- | And, | 5-FU, | Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer |
| - | in-vivo, | CRC, | HCT116 | - | in-vitro, | CRC, | SW480 |
| 1294- | And, | 5-FU, | Andrographolide reversed 5-FU resistance in human colorectal cancer by elevating BAX expression |
| - | in-vitro, | CRC, | HCT116 |
| 586- | Api, | 5-FU, | 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma |
| - | in-vivo, | HCC, | NA |
| 589- | Api, | 5-FU, | Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro |
| - | in-vitro, | PC, | Bxpc-3 |
| 1000- | AS, | 5-FU, | Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation |
| - | vitro+vivo, | BC, | 4T1 |
| 2295- | Ba, | 5-FU, | Baicalein reverses hypoxia-induced 5-FU resistance in gastric cancer AGS cells through suppression of glycolysis and the PTEN/Akt/HIF-1α signaling pathway |
| - | in-vitro, | GC, | AGS |
| 1385- | BBR, | 5-FU, | Low-Dose Berberine Attenuates the Anti-Breast Cancer Activity of Chemotherapeutic Agents via Induction of Autophagy and Antioxidation |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 751- | Bor, | 5-FU, | Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line |
| - | in-vitro, | CRC, | DLD1 |
| 939- | Catechins, | 5-FU, | Targeting Lactate Dehydrogenase A with Catechin Resensitizes SNU620/5FU Gastric Cancer Cells to 5-Fluorouracil |
| - | vitro+vivo, | GC, | SNU620 |
| 2803- | CHr, | 5-FU, | Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells |
| - | in-vitro, | GC, | AGS |
| 405- | CUR, | 5-FU, | Curcumin activates a ROS/KEAP1/NRF2/miR-34a/b/c cascade to suppress colorectal cancer metastasis |
| - | vitro+vivo, | CRC, | HCT116 |
| 468- | CUR, | 5-FU, | Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability |
| - | vitro+vivo, | Liver, | HepG2 | - | vitro+vivo, | Liver, | 402 | - | vitro+vivo, | Liver, | Bel7 |
| 442- | CUR, | 5-FU, | Curcumin may reverse 5-fluorouracil resistance on colonic cancer cells by regulating TET1-NKD-Wnt signal pathway to inhibit the EMT progress |
| - | in-vitro, | CRC, | HCT116 |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 679- | EGCG, | 5-FU, | Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer |
| - | in-vitro, | CRC, | NA |
| 4781- | Lyco, | 5-FU, | Chemo, | Cisplatin, | Antioxidant and anti-inflammatory activities of lycopene against 5-fluorouracil-induced cytotoxicity in Caco2 cells |
| - | in-vitro, | Colon, | Caco-2 |
| 4535- | MAG, | 5-FU, | Magnolol and 5-fluorouracil synergy inhibition of metastasis of cervical cancer cells by targeting PI3K/AKT/mTOR and EMT pathways |
| - | in-vitro, | Cerv, | NA |
| 1678- | PBG, | 5-FU, | sericin, | In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/AKT/mTOR pathway |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | NA, | NA |
| 1952- | PL, | 5-FU, | Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR |
| - | in-vivo, | CRC, | HCT8 |
| 3398- | TQ, | 5-FU, | Impact of thymoquinone on the Nrf2/HO-1 and MAPK/NF-κB axis in mitigating 5-fluorouracil-induced acute kidney injury in vivo |
| - | in-vivo, | Nor, | NA |
| 4888- | ZER, | 5-FU, | Modulation of the tumor microenvironment by zerumbone and 5-fluorouracil in colorectal cancer by target in cancer-associated fibroblasts |
| - | in-vitro, | CRC, | CT26 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:191 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid